Actively Recruiting
Randomized Study Comparing Different Doses of BL0175 Injection in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Led by Shanghai Best-Link Bioscience, LLC · Updated on 2026-10-21
120
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are comparing the objective response rates ORR of different doses of BL0175 in postmenopausal women with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer. This phase 2 randomized trial aims to identify the optimal dose that balances efficacy and safety to determine the recommended phase 3 dose. Participants will receive BL0175 injection either at 250 mg or 500 mg doses. The 250 mg dose is given as a single intramuscular injection in one buttock, while the 500 mg dose is administered as two 250 mg injections, one in each buttock. Dosing occurs on Day 1 and Day 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle. Treatment continues until disease progression, unacceptable side effects, withdrawal, or study end. During the study, participants will have regular evaluations to monitor tumor response using blinded independent central review and investigator assessments over 12 months. Researchers will measure progression-free survival, clinical benefit rate, disease control, duration of response, overall survival, and adverse events. The study involves randomized group assignments and ongoing safety monitoring throughout treatment and follow-up periods.
CONDITIONS
Brief Title
A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer
Research Team
L
Lun Zhuo Fang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here